Changzhou Qianhong Bio-pharma Co. Ltd, a biochemical maker of polysaccharides and enzymes drugs, has commenced construction of phase two of its pharmaceuticals production facility at Changzhou National Hi-Tech District on November 28, it was reported Tuesday.
The company has invested CNY1bn and phase two adds 200 million tablets and 60 million injections to production, making molecular diagnosis reagents available for use by 20 million people.
The CNY1.2bn phase one project, which is already in operation, generated sales revenue of CNY1,070m in 2017. Phase two, in line with international standards, will concentrate on the research and development of innovative and first-of-its-class-in-China biological drugs with its own intellectual property rights, with the aim of treating patients with critical illnesses such as cancers and cardiovascular and cerebrovascular diseases.
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder